Melanotan I: What It Is and How the Tanning Peptide Works

At a glance

What is Melanotan I?

Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a potent activator of the skin's MC1R pigment receptor. Chemically it is the same molecule as afamelanotide, the approved drug sold as Scenesse. The distinction is the product and the use: gray-market "Melanotan I" is an unregulated, self-injected tanning product, not the approved, quality-controlled implant. It is not an approved medicine in that form.

How does it work?

Melanotan I activates MC1R on pigment-producing skin cells, which raises production of the dark pigment eumelanin, darkening the skin independently of UV exposure. The receptor pharmacology is well characterized. This describes how it produces pigmentation, separate from whether unregulated self-injection for tanning is effective or safe.

In a placebo-controlled study of 65 fair-skinned volunteers, epidermal melanin density rose an average of 41% in low-MED, burn-prone skin and 12% in high-MED skin. That result shows the molecule's pigment effect, not the quality or safety of gray-market vials.

Is it FDA-approved?

No, not as a tanning product. The identical molecule is FDA-approved as afamelanotide (Scenesse), a controlled-release implant for erythropoietic protoporphyria, a rare light-sensitivity disorder, given under medical supervision. Gray-market Melanotan I vials sold for cosmetic tanning are not Scenesse, carry none of its manufacturing or quality controls, and are not approved.

What does the research show?

The rigorous human data belong to the approved drug and a different use. Afamelanotide has clinical trial evidence for reducing phototoxicity in the rare disorder it treats, not for cosmetic tanning. There are no controlled human trials supporting unregulated self-injected Melanotan I for tanning, so its cosmetic benefit and safety as sold are unestablished.

Two placebo-controlled trials of the approved implant, reported in 2015, enrolled 168 adults with EPP, split by trial as shown below.

In the EU trial, patients also had 77 phototoxic reactions versus 146 (P = 0.04). The most common adverse events were headache, nausea, nasopharyngitis, and back pain, with mild implant-site hyperpigmentation in about one third of treated patients. These figures come from a medical implant used for EPP, so they say nothing about tanning vials.

Evidence strength

Low research: The receptor pharmacology is solid, but there is no controlled human evidence supporting unregulated self-injected tanning; the only rigorous human data belong to the approved drug for a different, medical use.

Sources: pharmacology and bioassay work on the afamelanotide molecule (Spichty et al., Journal of Pharmaceutical and Biomedical Analysis, 2012, DOI: 10.1016/j.jpba.2012.11.040), indexed on PubMed; and FDA records for the approved product Scenesse (afamelanotide). This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.